EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease

Lucie Simonis, Yannick Marcour, Jan Embacher, Philipp Hruska, Peter Andersen, Benedikt Mehl, Lorenz Balcar, Mathias Jachs, Michael Trauner, Aleksander Krag, Thomas Reiberger, Thomas-Matthias Scherzer und 4 weitere

Clinical Gastroenterology and Hepatology · 2026-05

DOI: 10.1016/j.cgh.2026.05.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-05. Verfasst von Lucie Simonis und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic La…. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Assessment of hepatic steatosis is key for diagnosis and monitoring of steatotic liver disease. Controlled attenuation parameter is widely used, but concerns regarding its measurement variability exist. We evaluated the repeatability and reproducibility of controlled attenuation parameter and FibroScan-aspartate aminotransferase score across different clinical steatotic liver disease settings and disease stages. METHODS: We assessed same-day repeatability in subjects with suspected steatotic liver disease in secondary care (cohort I, n = 40) and tertiary care (cohort II, n = 58). Different-day reproducibility within 28 days was assessed in 4 cohorts: suspected steatotic liver disease (cohort III, n = 37), suspected fibrosis (cohort IV, n = 163), compensated advanced steatotic liver disease (cohort V, n = 32), and clinically significant portal hypertension (cohort VI, n = 28). Agreement was evaluated using the intraclass correlation coefficient, Bland-Altman analysis, and minimal detectable change. Categorical agreement was assessed by observed agreement and Cohen's Kappa. RESULTS: Same-day controlled attenuation parameter agreement was moderate to good (intraclass correlation coefficient, 0.64-0.80), but variability was substantial, with a minimal detectable change of 57 to 69 dB/m, corresponding to a relative minimal detectable change of 18% to 25%. Agreement for dichotomized controlled attenuation parameter cutoffs was moderate to strong (Cohen's Kappa = 0.33-0.65). Across different days, controlled attenuation parameter reproducibility was lower and worsened with disease severity. Intraclass correlation coefficients ranged from 0.44 to 0.67 in cohorts with suspected steatotic liver disease/fibrosis, decreased to 0.52 in compensated advanced steatotic liver disease, and was poor in clinically significant portal hypertension. Correspondingly, minimal detectable change increased from 80 to 94 dB/m (26%-34%) in less advanced disease to 128 to 174 dB/m (49%-72%) in advanced disease. FibroScan-aspartate aminotransferase score showed higher reproducibility in cohorts III to V (intraclass correlation coefficient, 0.73-0.82; minimal detectable change, 0.19-0.33) but also declined in cohort VI (intraclass correlation coefficient, 0.54). CONCLUSIONS: The minimal detectable change of controlled attenuation parameter is >57 to 69 dB/m (>18%-25%) and substantially greater in a longitudinal setting and advanced disease.

Schlagwörter

Stichwörter der Autor:innen

CAPElastographyMinimal Detectable ChangeSmallest Detectable DifferenceTest–Retest Reliability

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine…
  • Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria.
  • Department of Gastroenterology and Hepatology, FLASH Centre for Liver Research, Odense University Hospital, Odense, Denmark; Faculty of Health Sciences, Institute of Clinical Research, University of Southern Denmark, Od…
  • Health and Prevention Center, Sanatorium Hera, Vienna, Austria.
  • Health and Prevention Center, Sanatorium Hera, Vienna, Austria; Department of Medicine I - Gastroenterology and Hepatology, University Hospital Wiener Neustadt, Wiener Neustadt, Austria.
  • Department of Gastroenterology and Hepatology, FLASH Centre for Liver Research, Odense University Hospital, Odense, Denmark; Department of Gastroenterology and Hepatology, Herlev Hospital, Herlev, Denmark.

Förderung

  • Novo Nordisk Foundation

Zitieren

APA

Simonis, L., Marcour, Y., Embacher, J., Hruska, P., Andersen, P., Mehl, B., Balcar, L., Jachs, M., Trauner, M., Krag, A., Reiberger, T., Scherzer, T. M., Mandorfer, M., Thiele, M., Lehmann, M., & Semmler, G. (2026). Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.05.006

Vancouver

Simonis L, Marcour Y, Embacher J, Hruska P, Andersen P, Mehl B, et al. Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.05.006

BibTeX
@article{Simonis2026,
  author = {Simonis, Lucie and Marcour, Yannick and Embacher, Jan and Hruska, Philipp and Andersen, Peter and Mehl, Benedikt and Balcar, Lorenz and Jachs, Mathias and Trauner, Michael and Krag, Aleksander and Reiberger, Thomas and Scherzer, Thomas-Matthias and Mandorfer, Mattias and Thiele, Maja and Lehmann, Mette and Semmler, Georg},
  title = {Reliability of Hepatic Steatosis Quantification by Controlled Attenuation Parameter in Steatotic Liver Disease},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.05.006}
}
Kostenlos starten →